CR20230362A - Inhibidores de cdk2 y métodos de uso de los mismos - Google Patents

Inhibidores de cdk2 y métodos de uso de los mismos

Info

Publication number
CR20230362A
CR20230362A CR20230362A CR20230362A CR20230362A CR 20230362 A CR20230362 A CR 20230362A CR 20230362 A CR20230362 A CR 20230362A CR 20230362 A CR20230362 A CR 20230362A CR 20230362 A CR20230362 A CR 20230362A
Authority
CR
Costa Rica
Prior art keywords
methods
same
cdk2
cdk2 inhibitors
inhibitors
Prior art date
Application number
CR20230362A
Other languages
English (en)
Inventor
John Paul Sherrill
Wojtek Michowski
Dale A Porter Jr
Carl Eric Schwartz
John Feutrill
Louise Clare Kirman
Justin Ripper
Thomas P Blaisdell
Original Assignee
Cedilla Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedilla Therapeutics Inc filed Critical Cedilla Therapeutics Inc
Publication of CR20230362A publication Critical patent/CR20230362A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente divulgación proporciona compuestos, composiciones de los mismos y métodos de uso de los mismos para la inhibición de CDK2, y el tratamiento de enfermedades y trastornos relacionados con CDK2.
CR20230362A 2021-01-29 2022-01-28 Inhibidores de cdk2 y métodos de uso de los mismos CR20230362A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163143360P 2021-01-29 2021-01-29
PCT/US2022/070409 WO2022165513A1 (en) 2021-01-29 2022-01-28 Cdk2 inhibitors and methods of using the same

Publications (1)

Publication Number Publication Date
CR20230362A true CR20230362A (es) 2023-11-23

Family

ID=82654899

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230362A CR20230362A (es) 2021-01-29 2022-01-28 Inhibidores de cdk2 y métodos de uso de los mismos

Country Status (21)

Country Link
US (2) US20240174680A1 (es)
EP (1) EP4284365A4 (es)
JP (1) JP2024505261A (es)
KR (1) KR20230142745A (es)
CN (1) CN117177744A (es)
AU (1) AU2022214618A1 (es)
BR (1) BR112023015210A2 (es)
CA (1) CA3208618A1 (es)
CL (1) CL2023002223A1 (es)
CO (1) CO2023010023A2 (es)
CR (1) CR20230362A (es)
DO (1) DOP2023000145A (es)
EC (1) ECSP23057264A (es)
GE (1) GEAP202316332A (es)
IL (1) IL304728A (es)
JO (1) JOP20230170A1 (es)
MX (1) MX2023008968A (es)
PE (1) PE20240050A1 (es)
PH (1) PH12023552079A1 (es)
TW (1) TW202239402A (es)
WO (1) WO2022165513A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230142745A (ko) 2021-01-29 2023-10-11 세딜라 테라퓨틱스, 인크. Cdk2 억제제 및 그의 사용 방법
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
TW202317560A (zh) 2021-06-26 2023-05-01 美商賽迪拉治療股份有限公司 Ｃｄｋ２抑制劑及其使用方法
WO2024026483A2 (en) * 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024026486A2 (en) * 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
TW202412763A (zh) * 2022-07-29 2024-04-01 美商賽迪拉治療股份有限公司 Cdk2抑制劑及使用彼等之方法
EP4561552A4 (en) * 2022-07-29 2026-07-15 Cedilla Therapeutics Inc CDK2 INHIBITORS AND THEIR METHODS OF USE
CA3263008A1 (en) * 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. CDK2 INHIBITORS AND THEIR METHODS OF USE
AU2023377064A1 (en) * 2022-11-09 2025-05-22 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
WO2026090509A1 (en) * 2024-10-25 2026-04-30 Architect Therapeutics, Inc. Spiro heterocyclic cdk2 inhibitors

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
SE0302811D0 (sv) 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
DE10360745A1 (de) 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
AU2005219438B2 (en) 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
EP1705177A1 (en) * 2005-03-23 2006-09-27 Schering Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
TW200800999A (en) 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
US8629147B2 (en) 2005-11-03 2014-01-14 Chembridge Corporation Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
WO2007103273A2 (en) * 2006-03-03 2007-09-13 Trustees Of Boston University Thioredoxin and thioredoxin reductase inhibitors
US20080247964A1 (en) 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2007140383A2 (en) 2006-05-30 2007-12-06 Neurogen Corporation Spirocyclic sulfonamides and related compounds
JP2010503675A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛、糖尿病および脂質代謝の障害の治療に有用なスピロ縮合アゼチジン誘導体
MX2010004875A (es) * 2007-10-29 2010-05-19 Schering Corp Derivados de tiazol y metodos para utilizarlos.
PE20091017A1 (es) 2007-10-31 2009-07-16 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
EP2440542B1 (en) 2009-06-08 2013-12-18 Grünenthal GmbH Substituted benzimidazoles, benzonthiazoles and benzoxazoles
EP2473056A4 (en) * 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
US8633183B2 (en) 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
EP2646428B1 (en) 2010-12-02 2016-06-01 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivatives, preparation processes and medical uses thereof
CN102952118B (zh) 2011-08-17 2016-03-23 上海迪诺医药科技有限公司 聚（adp-核糖）聚合酶抑制剂、制备方法及其用途
WO2013131010A2 (en) 2012-03-02 2013-09-06 Icahn School Of Medicine At Mount Sinai Function of chemokine receptor ccr8 in melanoma metastasis
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
WO2015048567A1 (en) 2013-09-26 2015-04-02 Sanford-Burnham Medical Research Institute Spirocyclic ebi2 modulators
US9920073B2 (en) 2013-10-04 2018-03-20 Drexel University Compositions useful for inhibiting HIV-1 infection and methods using same
MX358346B (es) 2014-04-04 2018-08-15 Syros Pharmaceuticals Inc Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
JP6581111B2 (ja) 2014-04-28 2019-09-25 メッドシャイン ディスカバリー インコーポレイテッド Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体
US9527856B2 (en) 2014-05-15 2016-12-27 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases
NZ726874A (en) 2014-05-19 2018-03-23 Merial Inc Anthelmintic compounds
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
CN105461693B (zh) 2014-09-26 2019-10-25 广东东阳光药业有限公司 Crth2拮抗剂化合物及其用途
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
HRP20220003T1 (hr) 2015-08-04 2022-04-01 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
US10323038B2 (en) 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2017156177A1 (en) * 2016-03-09 2017-09-14 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
MY200738A (en) 2017-05-23 2024-01-13 H Lundbeck As Pyrazole magl inhibitors
BR112020001157A2 (pt) 2017-07-21 2020-07-21 Sichuan Haisco Pharmaceutical Co., Ltd. compostos de peptídeo amida, método de preparação dos mesmos e uso em medicina
RU2020107039A (ru) 2017-08-29 2021-09-30 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Спироциклические соединения и способы их получения и применения
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
CN111902386A (zh) 2017-12-28 2020-11-06 瑞璞鑫(苏州)生物科技有限公司 作为fto抑制剂的苯基甲酮衍生物
CN110156674A (zh) 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
CA3129516A1 (en) * 2018-02-28 2019-09-06 The Trustees Of The University Of Pennsylvania Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
AU2019364417A1 (en) 2018-10-24 2021-05-20 Araxes Pharma Llc 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1H-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of G12C mutant KRAS protein for inhibiting tumor metastasis
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
EP3886844A4 (en) 2018-11-28 2022-08-24 H. Lundbeck A/S Methods of treating disease with magl inhibitors
EP3887373A1 (en) 2018-11-29 2021-10-06 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN111138358B (zh) 2019-12-17 2023-04-18 中国药科大学 Usp8抑制剂及其制备方法与应用
KR20230142745A (ko) 2021-01-29 2023-10-11 세딜라 테라퓨틱스, 인크. Cdk2 억제제 및 그의 사용 방법
TW202317560A (zh) 2021-06-26 2023-05-01 美商賽迪拉治療股份有限公司 Ｃｄｋ２抑制劑及其使用方法
WO2024026483A2 (en) 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024026486A2 (en) 2022-07-28 2024-02-01 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
CA3263008A1 (en) 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. CDK2 INHIBITORS AND THEIR METHODS OF USE
TW202412763A (zh) 2022-07-29 2024-04-01 美商賽迪拉治療股份有限公司 Cdk2抑制劑及使用彼等之方法
EP4561552A4 (en) 2022-07-29 2026-07-15 Cedilla Therapeutics Inc CDK2 INHIBITORS AND THEIR METHODS OF USE

Also Published As

Publication number Publication date
GEAP202316332A (en) 2023-12-11
US20230109076A1 (en) 2023-04-06
CO2023010023A2 (es) 2023-09-08
CL2023002223A1 (es) 2023-12-29
EP4284365A1 (en) 2023-12-06
CN117177744A (zh) 2023-12-05
ECSP23057264A (es) 2023-09-29
TW202239402A (zh) 2022-10-16
IL304728A (en) 2023-09-01
JOP20230170A1 (ar) 2023-07-27
KR20230142745A (ko) 2023-10-11
PH12023552079A1 (en) 2024-01-22
WO2022165513A1 (en) 2022-08-04
AU2022214618A1 (en) 2023-08-17
MX2023008968A (es) 2023-09-22
DOP2023000145A (es) 2023-10-31
BR112023015210A2 (pt) 2023-11-07
US20240174680A1 (en) 2024-05-30
US12065445B2 (en) 2024-08-20
EP4284365A4 (en) 2024-12-18
JP2024505261A (ja) 2024-02-05
PE20240050A1 (es) 2024-01-09
CA3208618A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
WO2024026483A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026486A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026479A3 (en) Cdk2 inhibitors and methods of using the same
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
MX2024014262A (es) Inhibidores de parg
PH12022551623A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
WO2021142448A3 (en) Tgf-beta inhibitors and use thereof
MX2022010944A (es) Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
WO2024026484A3 (en) Cdk2 inhibitors and methods of using the same
MX2022016434A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
WO2024026481A3 (en) Cdk2 inhibitors and methods of using the same
PH12022550497A1 (en) Perk inhibiting compounds
MX2021013602A (es) Inhibidores de jak.
MX2025007384A (es) Inhibidores de malt1
MX2025001279A (es) Aril-triazolilo y antagonistas gpr84 relacionados y usos de estos
SA523440403B1 (ar) Magl مثبط
MX2025000151A (es) Agonistas de trpml1 con oxazol y usos de los mismos
MX2025001280A (es) Antagonistas de gpr84 con piridona sustituidos y usos de estos